thyroid carcinoma
Conditions
Interventions
None listed
Sponsors
Radboud Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Group 1: -newly diagnosed patients with TC that are therapy naïve and are planned to receive conventional treatment by surgery followed by RAI. -no evidence of local or distant metastases Group 2: -patients with TC with evidence of distant metastases (either newly diagnosed patients who are therapy naïve or patients with persistent or recurrent disease) and are planned to receive conventional treatment by surgery followed by RAI. -at least 4 months since the previous treatment with RAI (in the patients who have had this treatment in the past) Group 3: -patients with MNG in which the decision has been taken to undergo surgery because of obstructive symptoms or for cosmetic reasons Group 4: -patients with MNG in which the decision has been taken to undergo RAI because of obstructive symptoms. Group 5: -healthy individuals without evidence of thyroid disease.
Exclusion criteria
Exclusion criteria: Excluded from participation in this study will be subjects who are/have: Mentally incompetent; Pregnant or breastfeeding; Known inflammatory or infectious diseases or an immunosuppressive status; Using medication interfering with the immune system; Reduced platelets counts or other conditions associated with an increased risk of bleeding. Severe comorbidities: other active malignancy (except for basal cell carcinoma), serious psychiatric pathology; A self-reported alcohol consumption of >21 units per week.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Transcriptional and epigenetic signature and function of TAMs, BM myeloid progenitors and circulating macrophages before and after treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Presence of circulating tumor cells (CTC) and changes in circulating metabolites (either tumor-derived or tumor-induced) concentrations (metabolomics) associated with the functional reprograming of the immune cells. | — |
Countries
Netherlands
Outcome results
None listed